Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
NCT ID: NCT00739167
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
74 participants
OBSERVATIONAL
2008-04-30
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying quality of life in patients undergoing embolization using yttrium Y 90 glass microspheres for primary or metastatic liver cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
NCT00956930
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
NCT03028311
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
NCT00003907
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00530010
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma
NCT00910572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Assess the quality of life (QOL) as defined by the presence or absence of physical, social, emotional, and functional distress in patients with primary or metastatic liver cancer undergoing treatment with radioembolization or transcatheter arterial embolization.
* Compare the time course of QOL measures between treatment groups in patients treated with these regimens.
* Compare the time course of QOL measures between patient subgroups defined by pre-treatment quality of life or tumor burden.
OUTLINE: Patients complete FACT-Hep version 4 surveys on quality of life prior to initiation of embolization, and at 2 weeks and 1 month after completion of embolization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Y90 Group
Patients receiving treatment with radioembolization.
No interventions assigned to this group
TACE Group
Patients receiving treatment with transcatheter arterial embolization
No interventions assigned to this group
RFA Group
Patients receiving treatment with radiofrequency ablation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of primary hepatocellular cancer or metastatic liver cancer
* Planning radioembolization or transcatheter arterial embolization using yttrium Y 90 glass microspheres
* No encephalopathy
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Bilirubin ≤ 3 mg/dL
* Able to comply with study procedures
PRIOR CONCURRENT THERAPY:
* No prior treatment with radioembolization or transcatheter arterial embolization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peggy Gilbertsen, RN, BS
Role: PRINCIPAL_INVESTIGATOR
Robert H. Lurie Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1358-1365.e1. doi: 10.1016/j.cgh.2013.04.028. Epub 2013 May 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NU-07Q1
Identifier Type: -
Identifier Source: secondary_id
NU-IRB-STU00002799
Identifier Type: -
Identifier Source: secondary_id
NU 07Q1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.